Literature DB >> 23388002

Genetic associations with valvular calcification and aortic stenosis.

George Thanassoulis1, Catherine Y Campbell, David S Owens, J Gustav Smith, Albert V Smith, Gina M Peloso, Kathleen F Kerr, Sonali Pechlivanis, Matthew J Budoff, Tamara B Harris, Rajeev Malhotra, Kevin D O'Brien, Pia R Kamstrup, Børge G Nordestgaard, Anne Tybjaerg-Hansen, Matthew A Allison, Thor Aspelund, Michael H Criqui, Susan R Heckbert, Shih-Jen Hwang, Yongmei Liu, Marketa Sjogren, Jesper van der Pals, Hagen Kälsch, Thomas W Mühleisen, Markus M Nöthen, L Adrienne Cupples, Muriel Caslake, Emanuele Di Angelantonio, John Danesh, Jerome I Rotter, Sigurdur Sigurdsson, Quenna Wong, Raimund Erbel, Sekar Kathiresan, Olle Melander, Vilmundur Gudnason, Christopher J O'Donnell, Wendy S Post.   

Abstract

BACKGROUND: Limited information is available regarding genetic contributions to valvular calcification, which is an important precursor of clinical valve disease.
METHODS: We determined genomewide associations with the presence of aortic-valve calcification (among 6942 participants) and mitral annular calcification (among 3795 participants), as detected by computed tomographic (CT) scanning; the study population for this analysis included persons of white European ancestry from three cohorts participating in the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium (discovery population). Findings were replicated in independent cohorts of persons with either CT-detected valvular calcification or clinical aortic stenosis.
RESULTS: One SNP in the lipoprotein(a) (LPA) locus (rs10455872) reached genomewide significance for the presence of aortic-valve calcification (odds ratio per allele, 2.05; P=9.0×10(-10)), a finding that was replicated in additional white European, African-American, and Hispanic-American cohorts (P<0.05 for all comparisons). Genetically determined Lp(a) levels, as predicted by LPA genotype, were also associated with aortic-valve calcification, supporting a causal role for Lp(a). In prospective analyses, LPA genotype was associated with incident aortic stenosis (hazard ratio per allele, 1.68; 95% confidence interval [CI], 1.32 to 2.15) and aortic-valve replacement (hazard ratio, 1.54; 95% CI, 1.05 to 2.27) in a large Swedish cohort; the association with incident aortic stenosis was also replicated in an independent Danish cohort. Two SNPs (rs17659543 and rs13415097) near the proinflammatory gene IL1F9 achieved genomewide significance for mitral annular calcification (P=1.5×10(-8) and P=1.8×10(-8), respectively), but the findings were not replicated consistently.
CONCLUSIONS: Genetic variation in the LPA locus, mediated by Lp(a) levels, is associated with aortic-valve calcification across multiple ethnic groups and with incident clinical aortic stenosis. (Funded by the National Heart, Lung, and Blood Institute and others.).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23388002      PMCID: PMC3766627          DOI: 10.1056/NEJMoa1109034

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  46 in total

1.  The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis.

Authors:  J R Ortlepp; R Hoffmann; F Ohme; J Lauscher; F Bleckmann; P Hanrath
Journal:  Heart       Date:  2001-06       Impact factor: 5.994

2.  A haplotype map of the human genome.

Authors: 
Journal:  Nature       Date:  2005-10-27       Impact factor: 49.962

3.  A new multipoint method for genome-wide association studies by imputation of genotypes.

Authors:  Jonathan Marchini; Bryan Howie; Simon Myers; Gil McVean; Peter Donnelly
Journal:  Nat Genet       Date:  2007-06-17       Impact factor: 38.330

4.  Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease.

Authors:  Sotirios Tsimikas; Emmanouil S Brilakis; Elizabeth R Miller; Joseph P McConnell; Ryan J Lennon; Kenneth S Kornman; Joseph L Witztum; Peter B Berger
Journal:  N Engl J Med       Date:  2005-07-07       Impact factor: 91.245

5.  Predictors of outcome in severe, asymptomatic aortic stenosis.

Authors:  R Rosenhek; T Binder; G Porenta; I Lang; G Christ; M Schemper; G Maurer; H Baumgartner
Journal:  N Engl J Med       Date:  2000-08-31       Impact factor: 91.245

6.  Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice.

Authors:  Esther Merki; Mark Graham; Adam Taleb; Gregor Leibundgut; Xiaohong Yang; Elizabeth R Miller; Wuxia Fu; Adam E Mullick; Richard Lee; Peter Willeit; Rosanne M Crooke; Joseph L Witztum; Sotirios Tsimikas
Journal:  J Am Coll Cardiol       Date:  2011-04-12       Impact factor: 24.094

7.  Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.

Authors:  Pia R Kamstrup; Anne Tybjaerg-Hansen; Rolf Steffensen; Børge G Nordestgaard
Journal:  JAMA       Date:  2009-06-10       Impact factor: 56.272

8.  An investigation of coronary heart disease in families. The Framingham offspring study.

Authors:  W B Kannel; M Feinleib; P M McNamara; R J Garrison; W P Castelli
Journal:  Am J Epidemiol       Date:  1979-09       Impact factor: 4.897

9.  Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts.

Authors:  Bruce M Psaty; Christopher J O'Donnell; Vilmundur Gudnason; Kathryn L Lunetta; Aaron R Folsom; Jerome I Rotter; André G Uitterlinden; Tamara B Harris; Jacqueline C M Witteman; Eric Boerwinkle
Journal:  Circ Cardiovasc Genet       Date:  2009-02

10.  Lipoprotein(a) as a cardiovascular risk factor: current status.

Authors:  Børge G Nordestgaard; M John Chapman; Kausik Ray; Jan Borén; Felicita Andreotti; Gerald F Watts; Henry Ginsberg; Pierre Amarenco; Alberico Catapano; Olivier S Descamps; Edward Fisher; Petri T Kovanen; Jan Albert Kuivenhoven; Philippe Lesnik; Luis Masana; Zeljko Reiner; Marja-Riitta Taskinen; Lale Tokgözoglu; Anne Tybjærg-Hansen
Journal:  Eur Heart J       Date:  2010-10-21       Impact factor: 29.983

View more
  236 in total

Review 1.  Lipoprotein (a): Coming of Age at Last.

Authors:  Joseph L Witztum; Henry N Ginsberg
Journal:  J Lipid Res       Date:  2016-02-02       Impact factor: 5.922

Review 2.  Update on lipoprotein(a) as a cardiovascular risk factor and mediator.

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  Curr Atheroscler Rep       Date:  2013-10       Impact factor: 5.113

Review 3.  Genome-wide association studies of late-onset cardiovascular disease.

Authors:  J Gustav Smith; Christopher Newton-Cheh
Journal:  J Mol Cell Cardiol       Date:  2015-04-11       Impact factor: 5.000

4.  DNA methylation of a PLPP3 MIR transposon-based enhancer promotes an osteogenic programme in calcific aortic valve disease.

Authors:  Ghada Mkannez; Valérie Gagné-Ouellet; Mohamed Jalloul Nsaibia; Marie-Chloé Boulanger; Mickael Rosa; Deborah Argaud; Fayez Hadji; Nathalie Gaudreault; Gabrielle Rhéaume; Luigi Bouchard; Yohan Bossé; Patrick Mathieu
Journal:  Cardiovasc Res       Date:  2018-09-01       Impact factor: 10.787

5.  Relationship of bone mineral density with valvular and annular calcification in community-dwelling older people: The Cardiovascular Health Study.

Authors:  Daniele Massera; Shuo Xu; Traci M Bartz; Anna E Bortnick; Joachim H Ix; Michel Chonchol; David S Owens; Eddy Barasch; Julius M Gardin; John S Gottdiener; John R Robbins; David S Siscovick; Jorge R Kizer
Journal:  Arch Osteoporos       Date:  2017-05-30       Impact factor: 2.617

Review 6.  Lipid Biomarkers for Risk Assessment in Acute Coronary Syndromes.

Authors:  Jeffrey W Meeusen; Leslie J Donato; Allan S Jaffe
Journal:  Curr Cardiol Rep       Date:  2017-06       Impact factor: 2.931

Review 7.  Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.

Authors:  Adam N Berman; Ron Blankstein
Journal:  Curr Cardiol Rep       Date:  2019-08-05       Impact factor: 2.931

8.  Effects of the coronary artery disease associated LPA and 9p21 loci on risk of aortic valve stenosis.

Authors:  Teresa Trenkwalder; Christopher P Nelson; Muntaser D Musameh; Ify R Mordi; Thorsten Kessler; Costanza Pellegrini; Radoslaw Debiec; Tobias Rheude; Viktor Lazovic; Lingyao Zeng; Andreas Martinsson; J Gustav Smith; Jesper R Gådin; Anders Franco-Cereceda; Per Eriksson; Jonas B Nielsen; Sarah E Graham; Cristen J Willer; Kristian Hveem; Adnan Kastrati; Peter S Braund; Colin N A Palmer; Amparo Aracil; Oliver Husser; Wolfgang Koenig; Heribert Schunkert; Chim C Lang; Christian Hengstenberg; Nilesh J Samani
Journal:  Int J Cardiol       Date:  2018-11-17       Impact factor: 4.164

9.  Lp(a) [Lipoprotein(a)]-Related Risk of Heart Failure Is Evident in Whites but Not in Other Racial/Ethnic Groups.

Authors:  Brian T Steffen; Daniel Duprez; Alain G Bertoni; Weihua Guan; Michael Y Tsai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-10       Impact factor: 8.311

10.  Potential Role of H-Ferritin in Mitigating Valvular Mineralization.

Authors:  Katalin Éva Sikura; László Potor; Tamás Szerafin; Abolfazl Zarjou; Anupam Agarwal; Paolo Arosio; Maura Poli; Zoltán Hendrik; Gábor Méhes; Melinda Oros; Niké Posta; Lívia Beke; Ibolya Fürtös; György Balla; József Balla
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-03       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.